PORTLAND, OR
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)SPONDYLOARTHRITIS RESEARCH AND TREATMENT NETWORK, founded in 2013, is a small nonprofit in the Diseases & Disorders sector that reported $669K in total revenue in fiscal year 2023. Revenue fell 38% from the prior year — a significant decline worth monitoring. Expenses of $598K left a modest 11% surplus.
THE MISSION OF SPARTAN IS TO FOSTER RESEARCH AND EDUCATION IN SPONDYLOARTHRITIS IN THE UNITED STATES. SPARTAN MEMBERS ACCOMPLISH THIS MISSION BY ENGAGING IN SPECIFIC RESEARCH PROJECTS AND THROUGH AN ANNUAL MEETING, WHICH HIGHLIGHTS IMPORTANT EDUCATION AND RESEARCH PROGRAMS.
SPARTAN ANNUAL MEETINGSPARTAN HOLDS AN ANNUAL MEETING TO HIGHLIGHT ADVANCES IN SPONDYLOARTHRITIS RESEARCH AND TREATMENT AND ENCOURAGE POST-DOCTORAL FELLOWS TO ENGAGE IN THE SPARTAN MISSION OF...
SPARTAN ANNUAL MEETINGSPARTAN HOLDS AN ANNUAL MEETING TO HIGHLIGHT ADVANCES IN SPONDYLOARTHRITIS RESEARCH AND TREATMENT AND ENCOURAGE POST-DOCTORAL FELLOWS TO ENGAGE IN THE SPARTAN MISSION OF FOSTERING RESEARCH AND EDUCATION IN THE FIELD OF SPONDYLOARTHRITIS (SPA). THE RESEARCH AND EDUCATION MEETING IS ALSO AN OPPORTUNITY TO BRING TOGETHER EXPERT, DEDICATED RESEARCHERS TO IDENTIFY AND ADDRESS UNMET NEEDS IN THE FIELD OF SPA RESEARCH AND THERAPY. THE HYBRID MEETING IS ATTENDED BY SPARTAN MEMBERS FROM THROUGHOUT NORTH AMERICA - WITH ATTENDANCE OF 150 IN CLEVELAND, OHIO AND 50 VIRTUALLY. PRESENTERS IN THE SCIENTIFIC SESSIONS ARE THE PROMINENT INTERNATIONAL EXPERTS IN THEIR FIELDS. THE SPONDYLOARTHRITIS REVIEW COURSE IS A PRE-MEETING WORKSHOP FOR RHEUMATOLOGY FELLOWS, APPS, AND OTHER TRAINEES. WE CONDUCTED AN ULTRASOUND WORKSHOP ATTENDED BY MORE THAN 75 LEARNERS.SPARTAN RESEARCH PROJECTSCLASSIC (CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS INCEPTION COHORT)THE PRIMARY STUDY OBJECTIVE IS TO TEST ("VALIDATE") THE PERFORMANCE OF THE CURRENT ASAS CLASSIFICATION CRITERIA IN A PROSPECTIVE COHORT OF PATIENTS PRESENTING WITH UNDIAGNOSED CHRONIC BACK PAIN TO RHEUMATOLOGISTS AT NORTH AMERICAN SITES IN US, MEXICO, AND CANADA >/= 3 MONTHS DURATION WITH ONSET </= 45 YEARS OF AGE. THE STUDY WAS COMPLETED IN 2024 WITH 500 PATIENTS AT 25 SITES.BASIS (BIOMARKERS IN AXIAL SPONDYLOARTHRITIS INVESTIGATIVE STUDY) THE PRIMARY OBJECTIVE IS TO ESTABLISH A WELL-CHARACTERIZED BIOBANK FOR AXSPA AND IDENTIFY A DIAGNOSTIC BIOMARKER(S) UTILIZING A CROSS-SECTIONAL STUDY OF INDIVIDUALS WITHIN THE SPECTRUM OF AXSPA. THE BASIS STEERING COMMITTEE IS COLLABORATING WITH INDUSTRY PARTNERS AND INTENDS TO LAUNCH THE PROGRAM IN 2025.
SPARTAN GRANTSTHE MISSION OF SPARTAN IS TO ADVANCE RESEARCH AND EDUCATION TO IMPROVE THE CARE OF PATIENTS WITH SPONDYLOARTHRITIS. WE FEEL STRONGLY THAT LAYING THE FOUNDATION FOR THE NEXT GENERATION...
SPARTAN GRANTSTHE MISSION OF SPARTAN IS TO ADVANCE RESEARCH AND EDUCATION TO IMPROVE THE CARE OF PATIENTS WITH SPONDYLOARTHRITIS. WE FEEL STRONGLY THAT LAYING THE FOUNDATION FOR THE NEXT GENERATION OF RESEARCHERS AND LEADERS IN SPA IS AN IMPORTANT PORTAL TO ACHIEVE THIS MISSION. THE GOAL OF OUR GRANT PROGRAMS IS TO SUPPORT THE EARLY STAGES OF A FELLOW-LED RESEARCH PROJECT. WITH THE AIM OF ENCOURAGING FELLOWS TO TAKE UP RESEARCH PROJECTS UNDER MENTORS WITH EXPERTISE IN SPA, SPARTAN SUPPORTS TO 2 MENTORED FELLOWSHIP PROJECTS EACH YEAR ($10,000 PER PROJECT - WITH $5000 EACH FOR THE MENTOR AND MENTEE). SPARTAN'S EARLY CAREER INVESTIGATOR AWARD SUPPORTS EARLY CAREER INVESTIGATORS WHO ARE WORKING IN THE FIELD OF AXIAL SPONDYLOARTHRITIS AND HAS BEEN RENAMED THE EARLY CAREER INVESTIGATOR (ECI) AWARD WITH UP TO 2 NEW GRANTS SUPPORTED ($25,000 PER PROJECT PER YEAR FOR TWO YEARS) ANNUALLY. TRAVEL AWARDS GO TO THE TOP 3 ABSTRACTS TO SUPPORT TRAVEL TO INDUSTRY MEETINGS (3 AWARDS @ $1000 EACH).
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $669,112 | $1,072,855 | -0.4% |
| Expenses | $598,008 | $820,283 | -0.3% |
| Net Income | $71,104 | $252,572 | -0.7% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MATTHEW STOLL PHD MD | CHAIR | 10.00 |
Officer
Director
|
$0 | $0 | $0 |
| JOERG ERMANN MD | IMMEDIATE PAST CHAIR | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| IGNACIO GARCIA-VALLARDES MD | DIRECTOR | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| SIBA RAYCHAUDHURI MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MAUREEN DUBREUIL MD | TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| NIGIL HAROON PHD MD | VICE-CHAIR | 3.00 |
Officer
Director
|
$0 | $0 | $0 |
| JEAN LIEW MD MSC | DIRECTOR | 3.00 |
Director
|
$0 | $0 | $0 |
| MARINA MAGREY MD | SECRETARY | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| JOHN REVEILLE MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MOHAMAD BITTAR MD | DIRECTOR | 3.00 |
Director
|
$0 | $0 | $0 |
| AKIHIRO NAKAMURA MD PHD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| LISA SPIEGEL | EXECUTIVE DIRECTOR | 30.00 |
Officer
|
$106,300 | $0 | $106,300 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $669,112 | $598,008 | $2,444,182 | $71,104 |
| 2023 | $1,072,855 | $820,283 | $3,043,861 | $252,572 |
| 2022 | $1,197,948 | $2,108,521 | $2,490,686 | $-910,573 |
| 2021 | $903,973 | $1,434,698 | $3,243,342 | $-530,725 |
| 2020 | $1,051,122 | $451,083 | $3,730,850 | $600,039 |
| 2019 | $1,754,199 | $337,618 | $3,170,811 | $1,416,581 |
| 2019 | $2,005,831 | $451,796 | $2,974,584 | $1,554,035 |
Compare SPONDYLOARTHRITIS RESEARCH AND TREATMENT NETWORK with other nonprofits in Oregon and across the country.